Physician profile
Raymond Steele
NPI 1356881585
$887.97
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $214 · 2021: $265 · 2022: $114 · 2023: $236 · 2024: $58.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $246.95 | 2020-2024 | Ubrelvy, Vraylar, Linzess |
| Allergan, INC. | $115.65 | 2020 | |
| Amarin Pharma, INC. | $100.53 | 2020-2021 | |
| Glaxosmithkline, LLC. | $77.22 | 2020-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $52.27 | 2022-2023 | |
| Exact Sciences Corporation | $50.70 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $43.52 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $41.75 | 2021-2022 | |
| Lilly USA, LLC | $36.81 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.98 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.86 | 2021 | |
| Novo Nordisk INC | $17.33 | 2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $16.99 | 2024 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $15.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.73 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.